美股新聞 標題聯播 · 近 24 小時 242 則 · 24 個來源 · 最新 9/20 09:06
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · EDIT近 30 天 7 則 · 第 1 / 1 頁
- Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
- Editas Medicine Reports Inducement Grants to New Chief Medical Officer
- Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
- Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
- Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
- Editas Medicine to Participate in Upcoming Investor Conferences
- 4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
- Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
- Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
- EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
- Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
- Editas Medicine Announces Second Quarter 2026 Results and Business Updates
- Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
- Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
- Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
- CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
- Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
- Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
- Editas Medicine Announces Proposed Public Offering
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。